Alan Raffensperger has joined Swedish Orphan Biovitrum (Sobi) as chief operating officer with responsibility for sales & marketing, supply chain, procurement and IT.
Most recently he was chief executive of Benechill, a US medical device company within the hypothermia therapeutic field. From 2005–2010 he was employed by Amgen and served as executive director, Head of Nephrology from 2008–2010 based at the international headquarters in Switzerland, and general manager of the Nordic and Baltic region 2005–2008, based in Sweden.
Raffensperger was sales and marketing director at Roche Pharmaceuticals, Sweden 1999–2004; vice president, Global Marketing Diabetes Care at Roche Diagnostics 1996–1998 based in Germany, and business director Europe, Diabetes Care at Boeringher Mannheim 1994–1996, also based in Germany. He has also held leading positions within Pharmacia in Sweden and the US.
Sobi is an integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. Its product portfolio consists of around 60 marketed products as well as projects in the late clinical phase. Key therapeutic areas are inflammation and genetics and metabolism.
Sobi appoints chief operating officer
Alan Raffensperger takes over sales & marketing, supply chain, procurement and IT
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities
The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258
The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists